Eptifibatide patient counseling information

Eptifibatide
INTEGRILIN® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Eptifibatide
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Patient Counseling Information

Instruct patients to inform the doctor or healthcare provider about any medical conditions, medications, and allergies.

Manufactured for: Merck Sharp & Dohme Corp., a subsidiary of MERCK & CO., INC., Whitehouse Station, NJ 08889, USA

Manufactured by: Patheon Italia S.p.A, Ferentino, 03013, Italy

U.S. Patent Nos. 5,686,570; 5,747,447; and 5,756,451.

INTEGRILIN is a registered trademark of Millennium Pharmaceuticals, Inc.

USPI-I-69361303R011